Peptides for Muscle Loss (Sarcopenia)

Sarcopenia — age-related muscle loss — begins around 30 and accelerates after 60, with typical losses of 3-8% of lean mass per decade. It is driven by declining GH/IGF-1 signaling, mitochondrial dysfunction in muscle fibers, motor neuron loss, and chronic inflammation. The Midas Protocol addresses sarcopenia through: CJC-1295 + Ipamorelin (restore youthful GH pulsatility for lean mass maintenance), NAD+ (muscle mitochondrial function and SIRT1-mediated protein quality control), BPC-157 + TB-500 (tendon/ligament support for continued physical activity), and FOXO4-DRI (clear senescent cells driving muscle inflammation).

The Multi-Pathway Advantage

Single-compound approaches address one mechanism. The Midas Longevity Protocol addresses muscle loss (sarcopenia) from multiple angles simultaneously — repair, protection, regeneration, and senescent cell clearance. This is why a 12-compound protocol outperforms individual peptides for age-related conditions.